RESUMEN
Guidelines are inconsistent regarding annual QuantiFERON® TB Gold (QFT) tests in children taking biologics for dermatological conditions, and there is limited research on seroconversion, especially in regions with high tuberculosis (TB) prevalence. A retrospective review of pediatric patients taking biologic treatment for psoriasis or hidradenitis suppurativa (HS) who had one baseline and at least one follow-up QFT test was conducted to assess for seroconversion during treatment. Thirty-two patients were included, with no instances of seroconversion. These findings suggest that routine annual TB rescreening for pediatric patients taking biologic therapy for dermatologic conditions may not be necessary without additional TB exposure risks or symptomatology.
Asunto(s)
Hidradenitis Supurativa , Psoriasis , Seroconversión , Humanos , Estudios Retrospectivos , Hidradenitis Supurativa/tratamiento farmacológico , Hidradenitis Supurativa/diagnóstico , Hidradenitis Supurativa/inmunología , Niño , Masculino , Femenino , Adolescente , Psoriasis/tratamiento farmacológico , Ciudad de Nueva York , Ensayos de Liberación de Interferón gamma/métodos , Preescolar , Terapia Biológica/métodos , Tuberculosis/diagnósticoAsunto(s)
Dermatología , Atención Ambulatoria , Inequidades en Salud , Humanos , Pacientes AmbulatoriosAsunto(s)
Lidocaína , Bicarbonato de Sodio , Anestésicos Locales , Costos y Análisis de Costo , Epinefrina , HumanosRESUMEN
As the world's population of adults greater than 60 years old continues to increase, it is important to manage nail disorders that may impact their daily lives. Nail disorders may have significant impact on quality of life due to decreased functionality, extreme pain, or social embarrassment. In this review, we discuss nail disorders affecting older patients, including physiologic, traumatic, drug-induced, infectious, environmental, inflammatory, and neoplastic conditions. Diagnosis of these conditions involves a detailed history, physical examination of all 20 nails, and depending on the condition, a nail clipping or biopsy and/or diagnostic imaging. Nails grow even more slowly in older adults compared to younger individuals, and therefore it is important for accurate diagnosis, and avoidance of inappropriate management and delay of treatment. Increased awareness of nail pathologies may help recognition and management of nail conditions in older adults.
Nail disorders are common amongst older adults and may cause decreased functionality, pain, psychosocial problems and impact quality of life.Many nail conditions, both physiologic or pathologic, may have similar presentation in older adults. Confirmation testing is important to avoid inappropriate or delayed treatment.The increased frequency of comorbidities, drug interactions, polypharmacy, and mental or physical limitations with aging must be considered when managing care of older patients with nail disorders.
Asunto(s)
Enfermedades de la Uña , Uñas , Humanos , Enfermedades de la Uña/diagnóstico , Enfermedades de la Uña/terapia , Enfermedades de la Uña/etiología , Anciano , Uñas/patología , Calidad de Vida , Persona de Mediana Edad , Anciano de 80 o más AñosRESUMEN
Introduction: Onychopapilloma most commonly presents as longitudinal erythronychia, but diagnosis may be challenging in some cases due to varied clinical presentations. Most patients with onychopapillomas do not report associated pain but instead more commonly report functional interference. Case Report: We present a case of a 74-year-old female with a 5-year history of splitting and lifting of the right thumbnail, accompanied by nail sensitivity and intermittent painful throbbing. Clinical examination was significant for a less than 1 mm red line with distal onycholysis. Love's test and a cold test performed with ice pack were negative. X-ray of the right thumb was negative for erosion or exostosis. Nail biopsy was performed, and dermatopathology was consistent with onychopapilloma with a concomitant traumatic neuroma. Conclusion: We report a case of onychopapilloma with a concomitant traumatic neuroma. Subungual neuromas are extremely rare and have not previously been associated with onychopapilloma. Our case supports the expansion of the differential diagnosis for a painful nail and demonstrates the importance of diagnostic confirmation with biopsy and histopathology.
RESUMEN
Overall, 80%-90% of patients with psoriasis will have nail involvement at some point during their lifetime, and nail changes, on average, are more common in patients with longer disease duration. Since there is accelerated keratinocyte proliferation and cell turnover in cutaneous psoriasis plaques compared to normal skin, it has been hypothesized that psoriasis increases nail growth rate. We describe a case of a 44-year-old male with a 10-year history of cutaneous and nail psoriasis, with acceleration in nail growth rate for 2 years prior to presentation. Clinical examination of the fingernails showed very long nails with onychorrhexis, onycholysis, and koilonychia and scattered erythematous plaques involving the chest and arms. We report a case of rapid fingernail growth in a patient with a 10-year history of psoriasis with skin and nail manifestations. Our case supports the hypothesis that increased cell turnover in psoriasis patients affects nail growth rate.
RESUMEN
Pain and anxiety are common in patients undergoing nail surgery, and injection of local anesthetic is the most uncomfortable part of the procedure. Using a portable massager on the ipsilateral limb during nail injection can reduce pain and decrease patient anxiety. It is a simple and safe way to improve the patient experience during nail surgery.
Asunto(s)
Mano , Dolor , Humanos , Dolor/etiología , Dolor/prevención & control , Anestesia Local/métodos , Anestésicos Locales , Ansiedad/etiología , Ansiedad/prevención & controlRESUMEN
Nail unit melanoma (NUM) is an uncommon form of melanoma and is often diagnosed at later stages. Approximately two-thirds of NUMs are present clinically as longitudinal melanonychia, but longitudinal melanonychia has a broad differential diagnosis. Clinical examination and dermoscopy are valuable for identifying nail findings concerning malignancy, but a biopsy with histopathology is necessary to confirm a diagnosis of NUM. Surgical treatment options for NUM include en bloc excision, digit amputation, and Mohs micrographic surgery. Newer treatments for advanced NUM include targeted and immune systemic therapies. NUM in pediatric patients is extremely rare and diagnosis is challenging since both qualitative and quantitative parameters have only been studied in adults. There is currently no consensus on management in children; for less concerning melanonychia, some physicians recommend close follow-up. However, some dermatologists argue that the "wait and see" approach can cause delayed diagnosis. This article serves to enhance the familiarity of NUM by highlighting its etiology, clinical presentations, diagnosis, and treatment options in both adults and children.
Asunto(s)
Melanoma , Enfermedades de la Uña , Neoplasias Cutáneas , Humanos , Adulto , Niño , Neoplasias Cutáneas/diagnóstico , Neoplasias Cutáneas/epidemiología , Neoplasias Cutáneas/terapia , Dermoscopía , Melanoma/diagnóstico , Melanoma/epidemiología , Melanoma/terapia , Enfermedades de la Uña/diagnóstico , Enfermedades de la Uña/epidemiología , Enfermedades de la Uña/terapia , Diagnóstico DiferencialRESUMEN
INTRODUCTION: Psoriasis Area and Severity Index (PASI) and Physician's Global Assessment (PGA) are the most widely used outcome measures in clinical trials of biologics to treat psoriasis; however, these outcome measures vary in both their reliability and validity. As newer biologics approach complete clearance of psoriasis, it becomes important to have standardized, reproducible forms of measure to accurately compare treatment efficacy. The aim of this study was to evaluate the extent of and reasons for variation between PASI and PGA scores used in clinical trials. METHODS: A literature search was conducted of clinical trials meeting the inclusion criteria: phase 2 or 3, evaluation of treatment efficacy in reducing psoriasis severity, and use of PASI 90/100 and sPGA or PGA 0/1 as primary end points. RESULTS: Among the analyzed studies, 8 of 45 trials had a PASI-PGA variance of < 5%, 4 of 45 trials had a variance of 5-10%, and 33 trials had a variance of > 10%. The IMMvent and AMAGINE trials were the only two trials showing 0 variation between the PASI and PGA scores, testing adalimumab and brodalumab, respectively. Ustekinumab showed the highest variance of 61.9% in the IXORA-S trial. Limitations of this paper include a relatively low number of studies assessed because of the paucity of literature available. CONCLUSIONS: The use of both PASI and PGA as equivalent assessment tools for complete clearance is redundant and subject to high variability. Novel severity assessments should be developed that reduce calculation variation and take into account patient-oriented symptoms.